We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Roquefort Therapeutics Plc | ROQ | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.40 | 08:00:17 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.40 | 4.40 | 4.40 | 4.40 | 4.40 |
| Industry Sector |
|---|
| GENERAL FINANCIAL |
| Top Posts |
|---|
Posted at 23/5/2024 09:27 by z1co ttps://www.proactiveRoquefort Therapeutics signs out-licensing term sheet potentially worth an initial $10m Published: 07:24 23 May 2024 BST Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) said it has signed a term sheet to out-license its Midkine antibody portfolio to Dubai-based contract research group PDC, which would include an upfront sum of $10 million. The immuno-oncology group also expects to receive a non-dilutive equity stake in a special purpose vehicle (SPV) that PDC will use to develop the Midkine antibodies. The exclusive worldwide licence will last for 20 years. Within three years, PDC aims to have completed a phase I clinical trial for at least one of the antibodies. Following a successful trial, the SPV will be sold, with Roquefort earning around 24% of the sale proceeds. This share could be worth up to $50 million based on similar phase I trade sales, Roquefort said. "PDC is a great partner with a strong track record of completing clinical trials and we are confident they will accelerate the development of the Midkine antibodies into the clinic," added CEO Ajan Reginal. "Upon a successful phase I exit, this would create significant returns to the SPV shareholders. We believe this is a good deal for all parties and it validates our business model and highlights our deal-making capabilities. We expect to conclude this licensing agreement as soon as possible." The term sheet runs until December 31, allowing PDC to complete its due diligence. In a separate announcement, Roquefort said it is raising a gross £655,000 via the issue of unsecured convertible loan notes, which, along with current cash resources and cost-cutting measures, provides a funding runway for at least the next 12 months. Investors were also told Professor Sir Martin Evans will move from the role of chief scientific officer to become a non-executive director. Having completed his tenure as a non-exec, Dr Michael Stein will step down from the Roquefort board and will be replaced in 'due course'. |
Posted at 29/6/2023 07:47 by apotheki Roquefort Therapeutics plc / LSE:ROQAGM Statement Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, announces that at the Company's Annual General Meeting, to be held at 9.00am today, Chairman Stephen West will make the following statement: "As announced at the time of our year end results, 2022 saw Roquefort Therapeutics make significant progress, notably with the successful fundraise and completion of the acquisition of Oncogeni which pivoted the Company into a material oncology group. The acquisition significantly increased the Company's pre-clinical portfolio, therefore providing multiple opportunities for success. With partnership agreements to develop the portfolio at leading academic cancer research institutions signed, the foundations were laid for the Company to create value through our strategy. The excellent progress has continued into 2023 with the further advancement of the in-house development of a platform of novel mRNA cancer medicines and the signing of a strategic license agreement with Randox Laboratories to utilise Midkine antibodies in medical diagnostics, which will create significant time and cost advantages for clinical trials. We have made positive strides across our preclinical portfolio in 2023 with our Midkine antibody program targeting metastatic osteosarcoma producing encouraging in vivo pre-clinical data, which falls under the orphan drug category and carries significant commercial incentives. Our anti-cancer Midkine RNA oligonucleotide program targeting Midkine expressing cancers produced >90% in vitro efficacy in human liver and neuroblastoma cancer cells and this program will now progress into in vivo studies which are planned to complete before the end of this year. Safety and efficacy has already been demonstrated in in vivo studies for the MK cell therapy in leukemia and lymphomas, and for the siRNA therapy in colon cancer. The MK cell therapy is progressing well in development and the siRNA therapy is completing experiments to finalise the mode of delivery. Finally, we achieved positive in vitro results in our anti-cancer mRNA therapeutic in breast and liver cancer, where the studies demonstrated a statistically significant reduction in both cancer growth and migration. We have further consolidated our leadership position in the Midkine field by updating our filed patents to protect the mRNA compositions and methods. Our Midkine mRNA program is now progressing into in vivo studies at our laboratory in Stratford-upon-Avon. The Company's strategy is to discover and develop first-in-class cancer medicines within the highly attractive oncology market (forecast to surpass US$ 353.5 billion by 2030 at a CAGR of 8.4% in 2022-2030[1]). Within this field, Roquefort Therapeutics focuses on the cancers that are resistant to current medicines including breast, colon and liver cancer, where patient survival rates remain poor. The Company's programs focus on the novel cancer targets Midkine and STAT-6 both of which are associated with this poor survival[2],[3]. By blocking Midkine and STAT-6, the Company has shown in in vivo studies, that both the cancer growth rate and metastasis are reduced, which are the characteristics of first-in-class cancer medicines. All of our programs have met key R&D milestones on time and within budget and the progress made across all our programs is highly encouraging and in-keeping with our strategy. We look forward to updating shareholders on our pre-clinical and business development activities in due course." For a further update on the Company's recent developments and anticipated key milestones, Roquefort Therapeutics is giving a presentation via the Investor Meet Company platform at 11am on Wednesday, 5 July 2023: hxxps://www.investor |
Posted at 19/6/2023 07:50 by apotheki Commenting on the antibody program results, Ajan Reginald, Chief Executive Officer, said:"We decided to target metastatic osteosarcoma because of the high unmet medical need. There is a very poor 5-year survival rate of just 24%, and this poor survival is associated with over-expression of Midkine. Our rationale was that by targeting Midkine, we would be able to attack both primary tumours and metastasis. The in vivo results vindicate this approach and demonstrate the potential for a best-in-class medicine. We look forward to providing further information once the detailed results have been published. This strategy to focus on areas of high unmet medical need is underpinned by the orphan drug incentives (including market exclusivity, efficient clinical trials and tax incentives) and the higher market valuation and return on investment for the investors in companies with approved orphan medicines. Finally, this approach seems to reduce risk, with significantly higher clinical trial success rates particularly in phase 1 and 2 trials particularly with a biomarker, which in our case is Midkine. Therefore, this is a particularly promising scientific and commercial strategy which was delivered on time and on budget. We expect to announce more updates on our clinical progress and business development activities over the next quarter." |
Posted at 02/3/2023 07:56 by aimbagger Investor presentation https://twitter.com/ |
Posted at 22/12/2021 09:08 by the chairman elect !FOLLOWFEEDThe Prospectus and further information on the Company can be found on Roquefort Investment's website at: www.roquefortinvest. Stephen West, Executive Chairman, commented: "Today is an important milestone for Roquefort Investments as we complete our acquisition of Lyramid and recommence trading on the LSE. I would like to thank the team at Lyramid for their hard work and dedication to help make this transformational transaction happen. "The reception we have received from investors has been extremely positive and we are very excited to be embarking on the next of phase of our growth story as we continue Lyramid's development of Midkine inhibiting RNA therapeutic drugs targeting a number of diseases settings." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
